2-甲基-L-脯氨酸甲酯 (9ci) | 109837-32-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-甲基-L-脯氨酸甲酯 (9ci)
• 中文别名: 2-甲基-L-脯氨酸甲酯(9ci)；2-甲基-L-脯氨酸甲酯；(S)-2-甲基脯氨酸甲酯
• 英文名称: methyl 2-methyl-L-prolinate
• 英文别名: (S)-methyl 2-methylpyrrolidin-2-carboxylate；methyl (S)-2-methylpyrrolidine-2-carboxylate；(S)-Methyl 2-methylpyrrolidine-2-carboxylate；methyl (2S)-2-methylpyrrolidine-2-carboxylate
• CAS: 109837-32-3
• 化学式: C₇H₁₃NO₂
• mdl: MFCD13191669
• 分子量: 143.186
• InChiKey: CCNBDZFBJCGDIV-ZETCQYMHSA-N

物化性质

• 沸点：
  176℃
• 密度：
  1.017
• 闪点：
  61℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-甲基-L-脯氨酸甲酯 (9ci) 在 三乙胺 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 4.33h， 生成 N-benzyloxycarbonyl-glycyl-L-2-methylproline
  参考文献：
  名称：

  Development of glycine-α-methyl-proline-containing tripeptides with neuroprotective properties

  摘要：

  Herein is described the synthesis of novel glycine-alpha-methyl-proline-containing tripeptides (GP(Me)X tripeptides namely GP(Me)R, GP(Me)K, and GP(Me)H) with the aim of obtaining derivatives highly stable in human plasma and able to counteract neuroinflammatory processes that are distinctive of neurodegenerative pathologies. The syntheses of GP(Me)R, GP(Me)K, and GP(Me)H were all achieved both by introducing the Pro(Me) residue into the Gly-Pro-Arg (GPR) sequence in place of the native Pro in P2 position and replacing the basic amino acid Arg in P3 position by Lys or His.Results showed that all novel GP(Me)X tripeptides are stable in human plasma (t(1/2) > 51 h) and that GP(Me)H generating stable intramolecular H-bond in a C-11-turn by interaction of His imidazole ring and Gly carbonyl group restored physiological levels of nitric oxide deriving from neuronal NOS (nNOS) activity, thus preventing the inflammatory response by suppression of the NF-kB activity and, consequently, the expression of inflammatory genes such as inducibile NOS (iNOS). Therefore, GP(Me)H could be a lead compound for further development of peptidomimetics able to contrast neuroinflammatory processes. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.003
• 作为产物：
  描述：

  2-甲基吡咯烷-1,2-二羧酸-1-苄酯 在 palladium 10% on activated carbon 、 氢气 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.5h， 生成 2-甲基-L-脯氨酸甲酯 (9ci)
  参考文献：
  名称：

  SUBSTITUTED BENZOXAZOLES

  摘要：

  本发明涉及取代苯并恶唑及其制备方法，以及它们用于制备治疗和/或预防疾病，特别是心血管疾病，尤其是血栓性或血栓性栓塞疾病的药物的应用。

  公开号：

  US20160108027A1

文献信息

• DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20160002251A1

  公开（公告）日：2016-01-07

  The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

  本发明提供了一种二氢吡啶嗪-3,5-二酮衍生物或其盐，或化合物或盐的溶剂化合物，一种药物，一种药物组合物，一种钠依赖性磷酸盐转运体抑制剂，以及作为活性成分的化合物的高磷血症、继发性甲状旁腺功能亢进症、慢性肾功能衰竭、慢性肾病和与血管钙化相关的动脉硬化的预防和/或治疗剂，以及预防和/或治疗的方法。
• NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Buckman Brad

  公开号：US20110152246A1

  公开（公告）日：2011-06-23

  The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  实施例提供了一般式I、II、III、IV或V的化合物，以及包括药物组合物在内的组合物，其中包括一种主体化合物。实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• [EN] USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES<br/>[FR] UTILISATION DE DÉRIVÉS DE BENZIMIDAZOLE-PROLINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015083094A1

  公开（公告）日：2015-06-11

  The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.

  本发明涉及式(I)的化合物，其中Ar1和Ar2如描述中所述，并且它们作为治疗日落综合征的药物的用途，该发明还涉及制备这种化合物及其药用盐的方法。
• l-Proline derived nitrogenous steroidal systems: an asymmetric approach to 14-azasteroids
  作者：Ritesh Singh、Gautam Panda

  DOI：10.1039/c3ra42272k

  日期：——

  intramolecular SN2′ cyclization reaction for the construction of critical C-ring in the nitrogen impregnated steroidal architectures bearing unsaturation at Δ9(11) position. In the endeavour to synthesize some new congeners, the remote electronic impact of the electron donating groups in A ring and heteroatoms like oxygen in B ring, on the propensity of C-ring cyclization was also observed.

  已经描述了在温和的反应条件下使用L-脯氨酸来访问14-氮杂类固醇的有效手性池方法。关键步骤涉及分子内的S N 2'环化反应，以在含氮的甾族结构中在Δ9 （11）位置携带不饱和键，以构建关键的C环。为了合成一些新的同类物，还观察到了A环上给电子基团和B环上的氧等杂原子对C环环化倾向的远程电子影响。
• [EN] 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS<br/>[FR] DÉRIVÉS DE 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHÉNYL)-URÉE UTILISÉS COMME INHIBITEURS DE CXCR2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015181186A1

  公开（公告）日：2015-12-03

  The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

  这项发明涉及1-(3-磺酰基苯基)-3-(环戊-2-烯-1-基)脲衍生物，以及它们在治疗或预防由CXCR2受体介导的疾病和症状中的应用。此外，该发明涉及含有这些衍生物的组合物和它们的制备方法。